Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07152613
PHASE3

Corticosteroids for PJP in Non-HIV Immunocompromised Adults

Sponsor: Qingyuan Zhan

View on ClinicalTrials.gov

Summary

Pneumocystis jirovecii pneumonia (PJP) is one of the common severe complications in immunocompromised patients, with a reported mortality rate of 60-80%. Reducing mortality from PJP is crucial for improving outcomes in critically ill non-HIV immunocompromised patients and alleviating the burden on families and society. To address this medical challenge, our institution is conducting a study aimed at lowering PJP-related mortality. Specifically, we are performing an adaptive, randomized, open-label controlled trial in patients with severe PJP. The primary objective of this study is to scientifically evaluate the efficacy and safety of adjunctive corticosteroids at different dosages, in addition to early standard supportive care, for reducing mortality in severe PJP

Official title: An Embedded Adaptive Randomized Controlled Trial of Corticosteroid Therapy for Pneumocystis Jirovecii Pneumonia (PJP) in Non-HIV Immunocompromised Patients

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

240

Start Date

2025-09-08

Completion Date

2027-12-31

Last Updated

2025-09-09

Healthy Volunteers

No

Interventions

DRUG

Saline (0.9%, sterile, for infusion)

Saline for control

DRUG

Low Dose Corticosteroids

Methylprednisolone 0.5mg/kg ivgtt qd

DRUG

Moderate dose corticosteroids

Methylprednisolone 1.0mg/kg ivgtt qd